MENVEO Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Phase of Trial: Phase IV
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 01 Jun 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Dec 2014 Planned End Date changed from 1 Feb 2019 to 1 Aug 2018 as reported by ClinicalTrials.gov record.